非流行区鼻咽癌患者在调强放疗时代的回顾性多中心分析:土耳其放射肿瘤学会头颈癌组研究(TROD 01-001)
该研究为土耳其22个中心2015至2020年间收治的563例接受调强放疗的鼻咽癌患者的回顾性多中心分析,中位随访34个月,3年总生存率为89.5%,局部区域复发率8.2%,远处复发率8%。作者认为土耳其患者临床特征兼具东西方特点,生存结局与其他报道系列相当,但远处转移率似乎较低。
要点
- 563例接受调强放疗的鼻咽癌患者中,78.7%为III-IVA期,81.2%为未分化癌。
- 3年总生存率为89.5%,年龄≥50岁、男性、角化性组织学、T4、N3及晚期(III-IVA)患者生存率较低。
- 中位随访34个月后,局部区域复发率8.2%,远处复发率8%。
核心结论
- 土耳其鼻咽癌患者具有东西方混合的临床特征,生存结局与其他报道系列相当,但远处转移率似乎较低。
研究设计与样本
- 土耳其放射肿瘤学会头颈癌组开展的国家级、回顾性、多中心研究,纳入2015至2020年间在22个中心接受调强放疗的563例鼻咽癌患者。
主要发现
- 中位年龄48岁(范围9-83岁),年龄分布呈双峰,男性占74.1%,III-IVA期占78.7%。
- 角化性癌占3.9%,未分化癌占81.2%。
- 治疗方式包括同步放化疗(48.9%)、放疗联合诱导化疗(25%)或辅助化疗(19.5%)。
- 中位随访34个月(范围6-78个月)后,局部区域复发率8.2%,远处复发率8%。
- 3年总生存率为89.5%,年龄≥50岁、男性、角化性组织学、T4、N3及晚期(III-IVA)患者生存率较低。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We aimed to evaluate patients with nasopharyngeal carcinoma (NPC) in a nonendemic population. METHODS: In a national, retrospective, multicenteric study, 563 patients treated with intensity modulated radiotherapy at 22 centers between 2015 and 2020 were analyzed. RESULTS: Median age was 48 (9-83), age distribution was bimodal, 74.1% were male, and 78.7% were stage III-IVA. Keratinizing and undifferentiated carcinoma rates were 3.9% and 81.2%. Patients were treated with concomitant chemoradiotherapy (48.9%), or radiotherapy combined with induction chemotherapy (25%) or adjuvant chemotherapy (19.5%). After 34 (6-78) months follow-up, 8.2% locoregional and 8% distant relapse were observed. Three-year overall survival was 89.5% and was lower in patients with age ≥50, male sex, keratinizing histology, T4, N3 and advanced stage (III-IVA). CONCLUSIONS: Patients with NPC in Turkey have mixed clinical features of both east and west. Survival outcomes are comparable to other reported series; however, the rate of distant metastases seems to be lower.
引用
- Yildirim HC, Kupik GE, Mustafayev TZ, et al. A multicenter retrospective analysis of patients with nasopharyngeal carcinoma treated in IMRT era from a nonendemic population: Turkish Society for Radiation Oncology Head and Neck Cancer Group Study (TROD 01-001). Head Neck. 2023. PMID: 36854873. doi:10.1002/hed.27333
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。